Update shared on06 Aug 2025
Fair value Increased 4.44%A sharp decline in argenx’s future P/E ratio, despite slightly lower revenue growth forecasts, has contributed to a notable increase in the consensus analyst price target from €665.23 to €700.31.
What's in the News
- Argenx and Unnatural Products Inc. entered a strategic multi-target research collaboration to discover and develop oral macrocyclic peptide drugs for traditionally undruggable disease targets, with Argenx making an equity investment and up to $1.5 billion in milestones and royalties for UNP.
- Argenx will advance ARGX-119, a first-in-class agonist antibody for muscle-specific kinase (MuSK), to a registrational study in congenital myasthenic syndromes (CMS) after favorable safety and tolerability results from a Phase 1b study.
- The European Commission approved VYVGART (efgartigimod alfa) subcutaneous injection as a monotherapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment, following positive data from the ADHERE trial.
- Positive Phase 2 results for VYVGART (IV and SC) in primary Sjogren’s disease and idiopathic inflammatory myopathies (IIM) were presented, showing significant clinical improvement; efgartigimod also received FDA Fast Track designation for primary Sjogren’s disease.
Valuation Changes
Summary of Valuation Changes for argenx
- The Consensus Analyst Price Target has risen from €665.23 to €700.31.
- The Future P/E for argenx has significantly fallen from 26.38x to 20.96x.
- The Consensus Revenue Growth forecasts for argenx has fallen from 32.9% per annum to 30.1% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.